Laboratory Corporation of America said Thursday it had licensed a new blood testing technology for ovarian cancer from Yale University. The test is still under development.
Terms of the contract were not disclosed.
Ovarian cancer is the fourth most common cause of cancer in women and is the leading cause of gynecologic death.
"Ovarian cancer is one of the most difficult cancers to detect, especially in the earliest stages when it is more treatable," said Myla Lai-Goldman, executive vice president, chief scientific officer and medical director of LabCorp. "Consistent with our oncology strategy to fulfill unmet medical testing needs, LabCorp continues to dedicate resources to identifying and commercializing tests to help discriminate earlier between disease-free and cancer patients."